

SEQUENCE LISTING

<110> DINGIVAN, CHRISTINE A.

<120> METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE
DISORDERS BY ADMINISTERING INTEGRIN ALPHA-V-BETA-3 ANTAGONISTS IN
COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS

<130> 10271-053-999

<140>

<141>

<150> US 60/273,098

<151> 2001-03-02

<150> US 60/316,321

<151> 2001-08-31

<160> 17

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Mus sp.

<400> 1

Ser	Tyr	Asp	Met	Ser
1				5

<210> 2

<211> 7

<212> PRT

<213> Mus sp.

<400> 2

Lys	Val	Ser	Ser	Gly	Gly	Gly
1						5

<210> 3

<211> 8

<212> PRT

<213> Mus sp.

<400> 3

His	Asn	Tyr	Gly	Ser	Phe	Ala	Tyr
1							5

<210> 4

<211> 11

<212> PRT

<213> Mus sp.

<400> 4

Gln	Ala	Ser	Gln	Ser	Ile	Ser	Asn	His	Leu	His
1										10

<210> 5

<211> 11

<212> PRT

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Glu Ser Ile Ser Asn His
 20 25 30
 Leu His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Lys Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Gly Ser Trp Pro His
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 11
 <211> 5
 <212> PRT
 <213> Mus sp.

<400> 11
 Glu Tyr Tyr Met Tyr
 1 5

<210> 12
 <211> 17
 <212> PRT
 <213> Mus sp.

<400> 12
 Arg Ile Asp Pro Glu Asp Gly Ser Ile Asp Tyr Val Glu Lys Phe Lys
 1 5 10 15

Lys

<210> 13
 <211> 9
 <212> PRT
 <213> Mus sp.

<400> 13
 Gly Lys Phe Asn Tyr Arg Phe Ala Tyr
 1 5

<210> 14
 <211> 16
 <212> PRT
 <213> Mus sp.

<400> 14
 Arg Ser Ser Gln Ser Leu Leu His Ser Ser Gly Asn Thr Leu Asn Trp
 1 5 10 15

<210> 15
 <211> 7
 <212> PRT
 <213> Mus sp.

<400> 15
 Leu Val Ser Lys Leu Glu Ser
 1 5

<210> 16
 <211> 9
 <212> PRT
 <213> Mus sp.

<400> 16
 Met Gln Phe Thr His Tyr Pro Tyr Thr
 1 5

<210> 17
 <211> 347
 <212> PRT
 <213> Homo sapiens

<400> 17
 Met Val Ala Gly Ser Asp Ala Gly Arg Ala Leu Gly Val Leu Ser Val
 1 5 10 15
 Val Cys Leu Leu His Cys Phe Gly Phe Ile Ser Cys Phe Ser Gln Gln
 20 25 30
 Ile Tyr Gly Val Val Tyr Gly Asn Val Thr Phe His Val Pro Ser Asn
 35 40 45
 Val Pro Leu Lys Glu Val Leu Trp Lys Lys Gln Lys Asp Lys Val Ala
 50 55 60
 Glu Leu Glu Asn Ser Glu Phe Arg Ala Phe Ser Ser Phe Lys Asn Arg
 65 70 75 80
 Val Tyr Leu Asp Thr Val Ser Gly Ser Leu Thr Ile Tyr Asn Leu Thr
 85 90 95
 Ser Ser Asp Glu Asp Glu Tyr Glu Met Glu Ser Pro Asn Ile Thr Asp
 100 105 110
 Thr Met Lys Phe Phe Leu Tyr Val Asp Lys Thr His Thr Cys Pro Pro
 115 120 125
 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 130 135 140
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 145 150 155 160
 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
 165 170 175
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 180 185 190
 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
 195 200 205
 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
 210 215 220

Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys
225					230					235					240
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp
				245					250					255	
Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe
			260					265					270		
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu
		275					280					285			
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe
	290					295					300				
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly
305					310					315					320
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr
				325					330					335	
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys					
			340					345							

CHAD = CHAD